Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Meet the Expert: Daniel Seymour

Published: 1 Jul 2020

Views: 487

Rating:

Save

Daniel Seymour - BIO Ventures for Global Health, Seattle, USA

Following on from the webinar 'AC3T - Assessing, profiling, and building cancer clinical trial capacity in Africa' (hosted by the African Clinical Trials Consortium), in this Meet the Expert session Daniel Seymour answers submitted questions moderated by Prof Folakemi Odedina.

Watch Daniel Seymour's webinar here.

Find other sessions from the series here.

Related Videos

The Vanessa Moss Prize: celebrating research into cancer health disparities

Dr Olubukola Ayodele - University Hospitals of Leicester NHS Trust, Leicester, UK

The Vanessa Moss Prize: celebrating research into cancer health disparities ( Dr Olubukola Ayodele - University Hospitals of Leicester NHS Trust, Leicester, UK )

Tele-mentoring: Impact of project ECHO

Dr Sanjeev Arora - Project ECHO, Albuquerque, USA

Tele-mentoring: Impact of project ECHO ( Dr Sanjeev Arora - Project ECHO, Albuquerque, USA )

Choosing Wisely in pathology

Dr Angela Mlole - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in pathology ( Dr Angela Mlole - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

Choosing Wisely in radiology Tanzania

Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in radiology Tanzania ( Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German )

The use of IORT at Universitätsmedizin Mannheim hospital

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany

The use of IORT at Universitätsmedizin Mannheim hospital ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany )

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )

Why tumour markers are not recommended as screening tests

Dr Frederic Ting - Riverside Medical Center, Bacolod, Philippines

Why tumour markers are not recommended as screening tests ( Dr Frederic Ting - Riverside Medical Center, Bacolod, Philippines )

Choosing Wisely to mitigate financial toxicity in cancer care in Africa

Dr Penina Mnandi - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely to mitigate financial toxicity in cancer care in Africa ( Dr Penina Mnandi - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

More from ecancer